ISBN 10: 1490527850 / ISBN 13: 9781490527857
Usato / Quantità: 0
Copie del libro da altre librerie
Mostra tutte le  copie di questo libro

Libro

Purtroppo questa copia non è più disponibile. Di seguito ti proponiamo una lista di copie simili.

Descrizione:

This Book is in Good Condition. Clean Copy With Light Amount of Wear. 100% Guaranteed. Summary: Anemia is a common complication of chronic kidney disease (CKD). The management of anemia in CKD patients must strike an appropriate balance between stimulating generation of erythroblasts (erythropoiesis) and maintaining sufficient iron levels for optimum hemoglobin (Hb) production. As such, it is important to assess iron stores and the availability of iron for erythropoiesis, as adequate iron status is integral to both iron and anemia managements in CKD patients. Classical iron status tests, of which ferritin and transferrin saturation (TSAT) are the most widely used, exhibit large biological variability in the context of underlying inflammation of CKD. The accurate assessment of iron status is dependent on the validity and reliability of laboratory test results, and differences in test performance pose a dilemma regarding the most appropriate test to guide treatment decisions. Several novel biomarkers of iron status have been proposed as alternatives to the classical iron status tests. These include hemoglobin content of reticulocytes (CHr), reticulocyte hemoglobin equivalent (RetHe), percentage of hypochromic erythrocytes (%HYPO), erythrocyte zinc protoporphyrin (ZPP), soluble transferrin receptor (sTfR), and hepcidin. In addition, Superconducting Quantum Interference Devices (SQUIDs) are an alternative non-invasive means for detecting and quantifying liver iron content, via the paramagnetic properties of iron (magnetic resonance diminishes in the liver as iron concentration increases). The Tufts Evidence-based Practice Center (EPC) conducted a Comparative Effectiveness Review (CER) to systematically evaluate studies that examined the impact on patient-centered outcomes of using the newer laboratory biomarkers as a replacement for or as an add-on to classical laboratory biomarkers of iron status for assessing iron status and the management of iron deficiency in adult and pediatric CKD patients (nondialysis and dialysis). The Key Questions for the CER are presented below: Key Question 1 (Overarching Question) What is the impact on patient centered outcomes of using the newer laboratory biomarkers as a replacement for or an add-on to the older (classical) laboratory biomarkers of iron status for assessing iron status and management of iron deficiency in stages 3-5 CKD patients (nondialysis and dialysis), and in patients with a kidney transplant? Key Question 2 What is the test performance of newer markers of iron status as a replacement for or an addon to the older markers in stages 3-5 CKD patients nondialysis and dialysis, and in patients with a kidney transplant? a. What reference standards are used for the diagnosis of iron status in studies evaluating test performance? b. What are the adverse effects or harms associated with testing using newer and/or older markers of iron status? Key Question 3 In stages 3-5 nondialysis and dialysis CKD patients with iron deficiency, what is the impact of managing iron status based on newer laboratory biomarkers either alone or in addition to older laboratory biomarkers on intermediate outcomes (e.g., improvement in Hb levels, dose of erythropoiesis-stimulating agents, time in target Hb range), compared with managing iron status based on older laboratory biomarkers alone? a. What are the adverse effects or harms associated with the treatments guided by tests of iron status? Key Question 4 What factors affect the test performance and clinical utility of newer markers of iron status, either alone or in addition to older laboratory biomarkers, in stages 3-5 (nondialysis and dialysis) CKD patients with iron deficiency?. Codice inventario libreria

Su questo libro:

Book ratings provided by Goodreads):
0 valutazione media
(0 valutazioni)

Riassunto: Anemia is a common complication of chronic kidney disease (CKD). The management of anemia in CKD patients must strike an appropriate balance between stimulating generation of erythroblasts (erythropoiesis) and maintaining sufficient iron levels for optimum hemoglobin (Hb) production. As such, it is important to assess iron stores and the availability of iron for erythropoiesis, as adequate iron status is integral to both iron and anemia managements in CKD patients. Classical iron status tests, of which ferritin and transferrin saturation (TSAT) are the most widely used, exhibit large biological variability in the context of underlying inflammation of CKD. The accurate assessment of iron status is dependent on the validity and reliability of laboratory test results, and differences in test performance pose a dilemma regarding the most appropriate test to guide treatment decisions. Several novel biomarkers of iron status have been proposed as alternatives to the classical iron status tests. These include hemoglobin content of reticulocytes (CHr), reticulocyte hemoglobin equivalent (RetHe), percentage of hypochromic erythrocytes (%HYPO), erythrocyte zinc protoporphyrin (ZPP), soluble transferrin receptor (sTfR), and hepcidin. In addition, Superconducting Quantum Interference Devices (SQUIDs) are an alternative non-invasive means for detecting and quantifying liver iron content, via the paramagnetic properties of iron (magnetic resonance diminishes in the liver as iron concentration increases). The Tufts Evidence-based Practice Center (EPC) conducted a Comparative Effectiveness Review (CER) to systematically evaluate studies that examined the impact on patient-centered outcomes of using the newer laboratory biomarkers as a replacement for or as an add-on to classical laboratory biomarkers of iron status for assessing iron status and the management of iron deficiency in adult and pediatric CKD patients (nondialysis and dialysis). The Key Questions for the CER are presented below: Key Question 1 (Overarching Question) What is the impact on patient centered outcomes of using the newer laboratory biomarkers as a replacement for or an add-on to the older (classical) laboratory biomarkers of iron status for assessing iron status and management of iron deficiency in stages 3-5 CKD patients (nondialysis and dialysis), and in patients with a kidney transplant? Key Question 2 What is the test performance of newer markers of iron status as a replacement for or an addon to the older markers in stages 3-5 CKD patients nondialysis and dialysis, and in patients with a kidney transplant? a. What reference standards are used for the diagnosis of iron status in studies evaluating test performance? b. What are the adverse effects or harms associated with testing using newer and/or older markers of iron status? Key Question 3 In stages 3–5 nondialysis and dialysis CKD patients with iron deficiency, what is the impact of managing iron status based on newer laboratory biomarkers either alone or in addition to older laboratory biomarkers on intermediate outcomes (e.g., improvement in Hb levels, dose of erythropoiesis-stimulating agents, time in target Hb range), compared with managing iron status based on older laboratory biomarkers alone? a. What are the adverse effects or harms associated with the treatments guided by tests of iron status? Key Question 4 What factors affect the test performance and clinical utility of newer markers of iron status, either alone or in addition to older laboratory biomarkers, in stages 3-5 (nondialysis and dialysis) CKD patients with iron deficiency?

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Dati bibliografici

Condizione libro: Used

I migliori risultati di ricerca su AbeBooks

1.

Human Services, U. S. Department of Heal
ISBN 10: 1490527850 ISBN 13: 9781490527857
Nuovi Quantità: > 20
Print on Demand
Da
Books2Anywhere
(Fairford, GLOS, Regno Unito)
Valutazione libreria
[?]

Descrizione libro 2013. PAP. Condizione libro: New. New Book. Delivered from our US warehouse in 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND.Established seller since 2000. Codice libro della libreria IP-9781490527857

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 9,68
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 10,03
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

2.

U S Department of Heal Human Services, Agency for Healthcare Resea And Quality
Editore: Createspace Independent Publishing Platform, United States (2013)
ISBN 10: 1490527850 ISBN 13: 9781490527857
Nuovi Paperback Quantità: 10
Print on Demand
Da
The Book Depository
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Createspace Independent Publishing Platform, United States, 2013. Paperback. Condizione libro: New. Language: English . Brand New Book ***** Print on Demand *****.Anemia is a common complication of chronic kidney disease (CKD). The management of anemia in CKD patients must strike an appropriate balance between stimulating generation of erythroblasts (erythropoiesis) and maintaining sufficient iron levels for optimum hemoglobin (Hb) production. As such, it is important to assess iron stores and the availability of iron for erythropoiesis, as adequate iron status is integral to both iron and anemia managements in CKD patients. Classical iron status tests, of which ferritin and transferrin saturation (TSAT) are the most widely used, exhibit large biological variability in the context of underlying inflammation of CKD. The accurate assessment of iron status is dependent on the validity and reliability of laboratory test results, and differences in test performance pose a dilemma regarding the most appropriate test to guide treatment decisions. Several novel biomarkers of iron status have been proposed as alternatives to the classical iron status tests. These include hemoglobin content of reticulocytes (CHr), reticulocyte hemoglobin equivalent (RetHe), percentage of hypochromic erythrocytes ( HYPO), erythrocyte zinc protoporphyrin (ZPP), soluble transferrin receptor (sTfR), and hepcidin. In addition, Superconducting Quantum Interference Devices (SQUIDs) are an alternative non-invasive means for detecting and quantifying liver iron content, via the paramagnetic properties of iron (magnetic resonance diminishes in the liver as iron concentration increases). The Tufts Evidence-based Practice Center (EPC) conducted a Comparative Effectiveness Review (CER) to systematically evaluate studies that examined the impact on patient-centered outcomes of using the newer laboratory biomarkers as a replacement for or as an add-on to classical laboratory biomarkers of iron status for assessing iron status and the management of iron deficiency in adult and pediatric CKD patients (nondialysis and dialysis). The Key Questions for the CER are presented below: Key Question 1 (Overarching Question) What is the impact on patient centered outcomes of using the newer laboratory biomarkers as a replacement for or an add-on to the older (classical) laboratory biomarkers of iron status for assessing iron status and management of iron deficiency in stages 3-5 CKD patients (nondialysis and dialysis), and in patients with a kidney transplant? Key Question 2 What is the test performance of newer markers of iron status as a replacement for or an addon to the older markers in stages 3-5 CKD patients nondialysis and dialysis, and in patients with a kidney transplant? a. What reference standards are used for the diagnosis of iron status in studies evaluating test performance? b. What are the adverse effects or harms associated with testing using newer and/or older markers of iron status? Key Question 3 In stages 3-5 nondialysis and dialysis CKD patients with iron deficiency, what is the impact of managing iron status based on newer laboratory biomarkers either alone or in addition to older laboratory biomarkers on intermediate outcomes (e.g., improvement in Hb levels, dose of erythropoiesis-stimulating agents, time in target Hb range), compared with managing iron status based on older laboratory biomarkers alone? a. What are the adverse effects or harms associated with the treatments guided by tests of iron status? Key Question 4 What factors affect the test performance and clinical utility of newer markers of iron status, either alone or in addition to older laboratory biomarkers, in stages 3-5 (nondialysis and dialysis) CKD patients with iron deficiency?. Codice libro della libreria APC9781490527857

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 13,20
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

3.

Human Services, U. S. Department of Heal
ISBN 10: 1490527850 ISBN 13: 9781490527857
Nuovi Quantità: > 20
Print on Demand
Da
Pbshop
(Wood Dale, IL, U.S.A.)
Valutazione libreria
[?]

Descrizione libro 2013. PAP. Condizione libro: New. New Book.Shipped from US within 10 to 14 business days.THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Codice libro della libreria IP-9781490527857

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 10,31
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,42
In U.S.A.
Destinazione, tempi e costi

4.

U S Department of Heal Human Services, Agency for Healthcare Resea And Quality
Editore: Createspace Independent Publishing Platform, United States (2013)
ISBN 10: 1490527850 ISBN 13: 9781490527857
Nuovi Paperback Quantità: 10
Print on Demand
Da
The Book Depository US
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Createspace Independent Publishing Platform, United States, 2013. Paperback. Condizione libro: New. Language: English . Brand New Book ***** Print on Demand *****. Anemia is a common complication of chronic kidney disease (CKD). The management of anemia in CKD patients must strike an appropriate balance between stimulating generation of erythroblasts (erythropoiesis) and maintaining sufficient iron levels for optimum hemoglobin (Hb) production. As such, it is important to assess iron stores and the availability of iron for erythropoiesis, as adequate iron status is integral to both iron and anemia managements in CKD patients. Classical iron status tests, of which ferritin and transferrin saturation (TSAT) are the most widely used, exhibit large biological variability in the context of underlying inflammation of CKD. The accurate assessment of iron status is dependent on the validity and reliability of laboratory test results, and differences in test performance pose a dilemma regarding the most appropriate test to guide treatment decisions. Several novel biomarkers of iron status have been proposed as alternatives to the classical iron status tests. These include hemoglobin content of reticulocytes (CHr), reticulocyte hemoglobin equivalent (RetHe), percentage of hypochromic erythrocytes ( HYPO), erythrocyte zinc protoporphyrin (ZPP), soluble transferrin receptor (sTfR), and hepcidin. In addition, Superconducting Quantum Interference Devices (SQUIDs) are an alternative non-invasive means for detecting and quantifying liver iron content, via the paramagnetic properties of iron (magnetic resonance diminishes in the liver as iron concentration increases). The Tufts Evidence-based Practice Center (EPC) conducted a Comparative Effectiveness Review (CER) to systematically evaluate studies that examined the impact on patient-centered outcomes of using the newer laboratory biomarkers as a replacement for or as an add-on to classical laboratory biomarkers of iron status for assessing iron status and the management of iron deficiency in adult and pediatric CKD patients (nondialysis and dialysis). The Key Questions for the CER are presented below: Key Question 1 (Overarching Question) What is the impact on patient centered outcomes of using the newer laboratory biomarkers as a replacement for or an add-on to the older (classical) laboratory biomarkers of iron status for assessing iron status and management of iron deficiency in stages 3-5 CKD patients (nondialysis and dialysis), and in patients with a kidney transplant? Key Question 2 What is the test performance of newer markers of iron status as a replacement for or an addon to the older markers in stages 3-5 CKD patients nondialysis and dialysis, and in patients with a kidney transplant? a. What reference standards are used for the diagnosis of iron status in studies evaluating test performance? b. What are the adverse effects or harms associated with testing using newer and/or older markers of iron status? Key Question 3 In stages 3-5 nondialysis and dialysis CKD patients with iron deficiency, what is the impact of managing iron status based on newer laboratory biomarkers either alone or in addition to older laboratory biomarkers on intermediate outcomes (e.g., improvement in Hb levels, dose of erythropoiesis-stimulating agents, time in target Hb range), compared with managing iron status based on older laboratory biomarkers alone? a. What are the adverse effects or harms associated with the treatments guided by tests of iron status? Key Question 4 What factors affect the test performance and clinical utility of newer markers of iron status, either alone or in addition to older laboratory biomarkers, in stages 3-5 (nondialysis and dialysis) CKD patients with iron deficiency?. Codice libro della libreria APC9781490527857

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 13,83
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

5.

ISBN 10: 1490527850 ISBN 13: 9781490527857
Nuovi Quantità: > 20
Print on Demand
Da
BWB
(Valley Stream, NY, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Condizione libro: New. This item is Print on Demand - Depending on your location, this item may ship from the US or UK. Codice libro della libreria POD_9781490527857

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 16,33
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

6.

U. S. Department of Health and Human Services
Editore: Createspace
ISBN 10: 1490527850 ISBN 13: 9781490527857
Nuovi Paperback Quantità: 20
Print on Demand
Da
BuySomeBooks
(Las Vegas, NV, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Createspace. Paperback. Condizione libro: New. This item is printed on demand. Paperback. 52 pages. Dimensions: 11.0in. x 8.5in. x 0.1in.Anemia is a common complication of chronic kidney disease (CKD). The management of anemia in CKD patients must strike an appropriate balance between stimulating generation of erythroblasts (erythropoiesis) and maintaining sufficient iron levels for optimum hemoglobin (Hb) production. As such, it is important to assess iron stores and the availability of iron for erythropoiesis, as adequate iron status is integral to both iron and anemia managements in CKD patients. Classical iron status tests, of which ferritin and transferrin saturation (TSAT) are the most widely used, exhibit large biological variability in the context of underlying inflammation of CKD. The accurate assessment of iron status is dependent on the validity and reliability of laboratory test results, and differences in test performance pose a dilemma regarding the most appropriate test to guide treatment decisions. Several novel biomarkers of iron status have been proposed as alternatives to the classical iron status tests. These include hemoglobin content of reticulocytes (CHr), reticulocyte hemoglobin equivalent (RetHe), percentage of hypochromic erythrocytes (HYPO), erythrocyte zinc protoporphyrin (ZPP), soluble transferrin receptor (sTfR), and hepcidin. In addition, Superconducting Quantum Interference Devices (SQUIDs) are an alternative non-invasive means for detecting and quantifying liver iron content, via the paramagnetic properties of iron (magnetic resonance diminishes in the liver as iron concentration increases). The Tufts Evidence-based Practice Center (EPC) conducted a Comparative Effectiveness Review (CER) to systematically evaluate studies that examined the impact on patient-centered outcomes of using the newer laboratory biomarkers as a replacement for or as an add-on to classical laboratory biomarkers of iron status for assessing iron status and the management of iron deficiency in adult and pediatric CKD patients (nondialysis and dialysis). The Key Questions for the CER are presented below: Key Question 1 (Overarching Question) What is the impact on patient centered outcomes of using the newer laboratory biomarkers as a replacement for or an add-on to the older (classical) laboratory biomarkers of iron status for assessing iron status and management of iron deficiency in stages 3-5 CKD patients (nondialysis and dialysis), and in patients with a kidney transplant Key Question 2 What is the test performance of newer markers of iron status as a replacement for or an addon to the older markers in stages 3-5 CKD patients nondialysis and dialysis, and in patients with a kidney transplant a. What reference standards are used for the diagnosis of iron status in studies evaluating test performance b. What are the adverse effects or harms associated with testing using newer andor older markers of iron status Key Question 3 In stages 35 nondialysis and dialysis CKD patients with iron deficiency, what is the impact of managing iron status based on newer laboratory biomarkers either alone or in addition to older laboratory biomarkers on intermediate outcomes (e. g. , improvement in Hb levels, dose of erythropoiesis-stimulating agents, time in target Hb range), compared with managing iron status based on older laboratory biomarkers alone a. What are the adverse effects or harms associated with the treatments guided by tests of iron status Key Question 4 What factors affect the test performance and clinical utility of newer markers of iron status, either alone or in addition to older laboratory biomarkers, in stages 3-5 (nondialysis and dialysis) CKD patients with iron deficiency This item ships from La Vergne,TN. Paperback. Codice libro della libreria 9781490527857

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 18,27
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,39
In U.S.A.
Destinazione, tempi e costi

7.

Agency for and Quality and U. S. Department Human
ISBN 10: 1490527850 ISBN 13: 9781490527857
Nuovi Quantità: 1
Da
Castle Rock
(Pittsford, NY, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Condizione libro: Brand New. Book Condition: Brand New. Codice libro della libreria 97814905278571.0

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 25,11
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,42
In U.S.A.
Destinazione, tempi e costi